Skip to main content

Tekla Capital Management LLC

SEC CIK
0001300336
Latest filing
Aug 10, 2023

The latest 13F from Tekla Capital Management LLC covers Q2 2023 (filed Aug 10, 2023): 166 long positions worth $2.56B. The top 10 holdings make up 40.3% of the portfolio, and the largest is Amgen Inc (AMGN) at 5.4%. Livermore has 10 filings on Form 13F from this institution, going back to Q1 2021.

What changed in Q2 2023

Share counts compared with Q1 2023: how many positions were new, added to, reduced or sold out, and the biggest buys and sells. Dollar amounts are estimated at the quarter-end prices implied by the filing.

Full comparison
New
9
Est. +$47.5M
Added
28
Est. +$138.8M
Reduced
31
Est. −$209.9M
Sold out
20
Est. −$75.0M

Top 5 holdings

Share of this quarter's portfolio value

  1. AMGNAmgen Inc
    5.4%$136.9MHistory
  2. JNJJohnson & Johnson
    4.7%$119.5MHistory
  3. GILDGilead Sciences, Inc.
    4.6%$118.2MHistory
  4. REGNRegeneron Pharmaceuticals, Inc.
    4.5%$116.0MHistory
  5. VRTXVertex Pharmaceuticals Inc
    4.4%$111.9MHistory

Share of portfolio

Top 5 holdings and the other 161 positions, by share of portfolio value

  1. AMGN5.4%
  2. JNJ4.7%
  3. GILD4.6%
  4. REGN4.5%
  5. VRTX4.4%
  6. Other 161 positions76.4%

Biggest buys

New and added positions, by estimated amount bought

  1. MRKMerck & Co., Inc.
    +$20.3MAddedHistory
  2. AMGNAmgen Inc
    +$13.5MAddedHistory
  3. REGNRegeneron Pharmaceuticals, Inc.
    +$13.2MAddedHistory
  4. PODDInsulet Corp
    +$12.6MNewHistory
  5. THCTenet Healthcare Corp
    +$12.1MNewHistory

Largest weight increases

New and added positions, by percentage points of the portfolio gained

  1. MRKMerck & Co., Inc.
    +1.05 pp2.2% → 3.3%History
  2. PODDInsulet Corp
    +0.49 pp0.0% → 0.5%History
  3. IQVIQVIA Holdings Inc.
    +0.48 pp0.5% → 1.0%History
  4. THCTenet Healthcare Corp
    +0.47 pp0.0% → 0.5%History
  5. BAXBaxter International Inc
    +0.47 pp0.1% → 0.6%History

Biggest sells

Reduced and sold-out positions, by estimated amount sold

  1. LLYEli Lilly & Co
    −$35.4MReducedHistory
  2. CICigna Group
    −$24.2MReducedHistory
  3. SGENSeagen Inc.
    −$21.6MReducedHistory
  4. BMYBristol Myers Squibb Co
    −$13.1MReducedHistory
  5. UNHUnitedHealth Group Inc
    −$13.1MReducedHistory

Largest weight decreases

Reduced and sold-out positions, by percentage points of the portfolio lost

  1. SGENSeagen Inc.
    −0.89 pp1.7% → 0.8%History
  2. CICigna Group
    −0.72 pp1.8% → 1.1%History
  3. SRPTSarepta Therapeutics, Inc.
    −0.69 pp1.5% → 0.8%History
  4. ILMNIllumina, Inc.
    −0.61 pp3.1% → 2.5%History
  5. BMYBristol Myers Squibb Co
    −0.60 pp1.8% → 1.1%History

Metrics

13F metrics for Q2 2023, computed only from the numbers in the filings. Definitions below.

Portfolio value
$2.56B
−$71.2M (−2.7%) vs. prior quarter
Positions
166
−11 vs. prior quarter
Top 10 concentration
40.3%
Top 10 as share of value
Turnover
7.2%
Q2 2023, one quarter
Average holding period
9.3 quarters
Weighted by value

How these are calculated

  • Portfolio value: the market value of all long positions in the 13F, as reported at quarter end, excluding options.
  • Top 10 concentration: the combined value of the 10 largest positions as a share of portfolio value.
  • Turnover: the smaller of this quarter's estimated purchases and estimated sales, divided by the average of this and last quarter's portfolio value. Estimates multiply the change in shares by the quarter-end price implied by the filing (market value divided by shares); new positions use this quarter's value and sold-out positions last quarter's. Only positions reported in shares count, and it is not calculated when the previous quarter was not filed.
  • Average holding period: how many consecutive quarters each current position has been held (including this one; a quarter without the position or without a filing starts the count over), weighted by this quarter's value. Counting starts with the first 13F in Livermore (Q1 2021), so positions held before then are understated.

13F filings by quarter

10 quarters, going back to Q1 2021. Bars show each quarter's 13F portfolio value; quarters without a filing are left blank.

Peak $3.11B (Q4 2021)

Q1 2021: $2.91BQ2 2021: $3.08BQ3 2021: $3.11BQ4 2021: $3.11BQ1 2022: $2.85BQ2 2022: $2.54BQ3 2022: $2.44BQ4 2022: $2.65BQ1 2023: $2.63BQ2 2023: $2.56B
Q1 2021Q2 2023
13F filings of Tekla Capital Management LLC by quarter
QuarterFiledPositionsValueTop 3 holdingsChangesFiling
Q2 2023Aug 10, 2023166$2.56BAMGNJNJGILDvs. Q1 2023SEC
Q1 2023May 10, 2023177$2.63BAMGNGILDREGNvs. Q4 2022SEC
Q4 2022Feb 10, 2023172$2.65BUNHAMGNGILDvs. Q3 2022SEC
Q3 2022Nov 1, 2022168$2.44BUNHJNJAMGNvs. Q2 2022SEC
Q2 2022Jul 29, 2022177$2.54BUNHAMGNGILDvs. Q1 2022SEC
Q1 2022May 13, 2022175$2.85BUNHAMGNREGNvs. Q4 2021SEC
Q4 2021Feb 14, 2022171$3.11BUNHMRNAAMGNvs. Q3 2021SEC
Q3 2021Nov 12, 2021172$3.11BMRNAAMGNUNHvs. Q2 2021SEC
Q2 2021Aug 13, 2021189$3.08BUNHAMGNGILDvs. Q1 2021SEC
Q1 2021May 14, 2021196$2.91BGILDAMGNJNJ–SEC

13D and 13G filings

Companies where Tekla Capital Management LLC reports owning 5% or more on Schedule 13D or 13G, and its latest filings.

Current stakes of 5% or more

Tekla Capital Management LLC does not currently report owning 5% or more of any company.

Latest filings

3 filings on file made by Tekla Capital Management LLC or listing it as a reporting person, newest first.

Schedule 13D and 13G filings by Tekla Capital Management LLC
CompanyFiled (ET)FormStakeChangeEvent dateFiling
RLYBRallybio CorpJan 23, 202313G/AOld format–––SEC
RLYBRallybio CorpJan 21, 202213GOld format–New–SEC
Zyla Life SciencesJan 29, 20218:51 AM ET13G/AOld format–––SEC